China SXT Pharmaceuticals Inc. (SXTC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.25 (-8.45% 1D, market cap $367.7K). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 485 tracked Industrials issuers, SXTC ranks #359 in composite RQD confidence.
Within the Industrials sector (Diversified Equities), SXTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 21.9%, and ROIC of —. By comparison, NUR (Nuran Wireless Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $9.0M) and JBDI (JBDI Holdings Limited) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $22.9M). Among the 5-stock peer group, SXTC leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).
Per SXTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001723980), China SXT Pharmaceuticals Inc. generated $1.1M in revenue (-34.6% YoY), -$6.2M in net income, and -$4.0M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 21.9% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While SXTC currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Industrials with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($167.50) and Max Pain ($3.41) forces dealer call-delta covering toward $8,794,800.00.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
China SXT Pharmaceuticals Inc. (SXTC) dropped -8.45% to $3.25, trading at 2% of its 52-week range ($2.98 – $8376000). Stretched risk/reward at current multiples (22% profit margin) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
STAK Inc-A led US stock gainers with a 63.5% jump and POMDOCTOR LTD - ADR led losers with a 39.83% drop in the Oct. 22, 2026 session.
Today's US session saw top gainers rise as much as 111.0% and top losers fall as much as 36.86%, with SHFS leading gainers and AVTX leading losers.
US-listed gap movers on October 22, 2026: SHFS, STAK and PFSA led gap-up stocks, while POM, AVTX and SXTC led gap-down stocks.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SXTC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SXTC. Explore sector supply chains on /butterfly.
Across 485 tracked Industrials securities in the Roarable RQD universe, China SXT Pharmaceuticals Inc. (SXTC) ranks #359 by composite RQD confidence (38/100, grade D-) and #485 by equity capitalization ($367.7K). Within this direct 5-issuer industry benchmark cohort, SXTC leads on earnings valuation at N/A trailing P/E, while IDXG leads on capital efficiency and profitability with 16.2% ROIC and 62.3% gross margin. IDXG currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with SXTC at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SXTC
ACTIVE
China SXT Pharmaceuticals Inc. | D- | 38/100 | — | 21.9% | — | -8.45% | $367.7K | Benchmark Subject |
| NUR Nuran Wireless Inc. | D | 46/100 | — | — | — | +2.93% | $9.0M | /nur-vs-sxtc → |
| JBDI JBDI Holdings Limited | D | 46/100 | — | 49.9% | — | -2.08% | $22.9M | /jbdi-vs-sxtc → |
| IDXG Interpace Biosciences Inc. | C | 64/100 | — | 62.3% | 16.2% | -2.23% | $23.2M | /idxg-vs-sxtc → |
| BHST BioHarvest Sciences Inc. | D- | 35/100 | — | 59.3% | -35.0% | 0.00% | $37.6M | /bhst-vs-sxtc → |
In its most recent audited fiscal period (FY2025, filed 2026-03-31), China SXT Pharmaceuticals Inc. (SXTC) reported GAAP revenue of $1.1M (-34.6% vs. FY2024 revenue of $1.7M , and -41.0% cumulative change since FY2023) , GAAP net income of -$6.2M, operating cash flow of -$4.0M, and free cash flow of -$4.0M (-71.1% YoY). On the balance sheet, SXTC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $1.1M | -$6.2M | -$4.0M | -$4.0M | — | — |
| FY2024 (FY) | 2025-03-31 | $1.7M | -$3.3M | -$2.3M | -$2.3M | — | — |
| FY2023 (FY) | 2024-03-31 | $1.9M | -$3.1M | -$1.9M | -$1.9M | — | — |
As of 2026-11-02, China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.25 (-8.45% 1D, market cap $367.7K). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 485 tracked Industrials issuers, SXTC ranks #359 in composite RQD confidence.
Within the Industrials sector (Diversified Equities), SXTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 21.9%, and ROIC of —. By comparison, NUR (Nuran Wireless Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $9.0M) and JBDI (JBDI Holdings Limited) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $22.9M). Among the 5-stock peer group, SXTC leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).
Per SXTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001723980), China SXT Pharmaceuticals Inc. generated $1.1M in revenue (-34.6% YoY), -$6.2M in net income, and -$4.0M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SXTC last traded at $3.25 (-8.45% on volume of 108,827 shares), positioning the stock -98.06% below its 50-day simple moving average ($167.50) and -99.98% below its 200-day simple moving average ($14,902.71). Across its 52-week range of $2.98 to $8,376,000.00, SXTC sits at the 0.0% percentile with a 14-day RSI of 27.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.84 to $3.66).
Why SXTC Stock dropped -8.45% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (22% profit margin) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SXTC scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
For a prospective investor evaluating the stock today, the rating points to a weak fundamental profile across most pillars. The strongest pillar relative to its maximum is the macro fit score, and even that is below half of its weight. Upside drivers are not evident in the source data; the main drivers of the score are negative cash-flow metrics and weak forensic indicators. The recent news flow includes a registered direct offering, which the headlines flag as carrying significant dilution potential. Valuation cannot be assessed on earnings multiples because P/E and EPS are not available in source data, and the market data shows negative operating and net margins.
China SXT Pharmaceuticals Inc. (SXTC) is listed on NASDAQ and classified under the Industrials sector and Diversified Equities industry, per the profile section. The source data does not describe the company's products, customers, or revenue model. The financials show reported revenue of $1.1M for FY 2025, $1.7M for FY 2024, and $1.9M for FY 2023. Market data shows a gross margin of 21.9%.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1.1M | $-7.1M | $-6.2M | N/A | $-4.0M | N/A | N/A |
| FY 2024 | $1.7M | $-2.7M | $-3.3M | N/A | $-2.3M | N/A | N/A |
| FY 2023 | $1.9M | $-2.5M | $-3.1M | N/A | $-1.9M | N/A | N/A |
Per the SEC financials, revenue declined across the three periods while operating losses widened from $-2.5M in FY 2023 to $-7.1M in FY 2025. Market data shows an operating margin of -60% and a net margin of -60%. Per the Roarable RQD rating, ROIC is 0% and the Altman Z-Score is 2.5, while the Piotroski F-Score is 1 out of 9. The RQD rating reports Debt/Equity of 0.5, though the financials table lists debt as N/A for each period, so the balance sheet posture cannot be fully reconciled from the source data.
Per the recent news section, the most prominent headline reports a $12 Million registered direct offering "With Significant Dilution Potential," which is a risk watch item. Multiple outlets (Yahoo Finance, Stock Titan) report the same $12 Million offering. A Quiver Quantitative item describes a thin-float rebound, tagged as a catalyst. A kalkine.ca item asks why the stock collapsed 88% after an offering. A Moomoo item covers analyst ratings, but the content is not included in the source data. The butterfly supply-chain graph lists supply chain as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for China SXT Pharmaceuticals Inc. (SXTC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering China SXT Pharmaceuticals Inc. (SXTC) market action, institutional positioning, and fundamental catalysts.
STAK Inc-A led US stock gainers with a 63.5% jump and POMDOCTOR LTD - ADR led losers with a 39.83% drop in the Oct. 22, 2026 session.
Welcome to the SXTC (China SXT Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Diversified Equities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SXTC, but look at what you are paying: current EV/EBITDA multiples with 21.9% gross margins. Unless China SXT Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SXTC, the market is fixating on short-term headline noise in Diversified Equities and ignoring the balance sheet and cash flow trajectory. At $3.55 (52-wk range $3.17 - $3.95), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).